Pérez Fidalgo J. A., García Fabregat L., Cervantes A., Margulies A., Vidall C., & Roila F. (2012). Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Annals of Oncology, 23( Suppl 7), vii167–vii173. 10.1093/annonc/mds294 [ PubMed] [ CrossRef] [ Google Scholar]

Frozen | BIG W Frozen | BIG W

Patient Neurotoxicity Questionnaire results: significantly lower grades of peripheral neuropathy in the intervention side ( p< .0001) Bhatnagar B., Gilmore S., Goloubeva O., Pelser C., Medeiros M., Chumsri S.,...Bao T. (2014). Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: A single-center experience. SpringerPlus, 3, Article number: 366. 10.1186/2193-1801-3-366 [ PMC free article] [ PubMed] [ CrossRef] [ Google Scholar] CTCAE results: Decrease in the incidence of ≥ grade 2 peripheral neuropathy in the intervention side ( p< .0001). The occurrence of ≥ grade 2 sensory neurotoxicity decreased from 76.1% to 21.4%, and that of motor neurotoxicity decreased from 57.1% to 26.2% Reduced incidence of ≥ grade 2 peripheral neuropathy in the intervention group (5.0%–9.1%) vs. the control group (22.5%–35.8%); p< .05 at the fourth cycle and p< .01 after the fifth cycle Christodoulou C., Tsakalos G., Galani E., & Skarlos D. V. (2006). Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. Annals of Oncology, 17( 2), 350Sato J., Mori M., Nihei S., Kumagai M., Takeuchi S., Kashiwaba M., & Kudo K. (2016). The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. Journal of Pharmaceutical Health Care and Sciences, 2, Article number: 33 One of the two studies that applied a relatively lesser amount of cooling as defined in this review achieved statistically significant benefits in the severity of peripheral neuropathy ( Tsuyuki et al., 2016). This prospective, self-controlled study included 42 breast cancer patients who received compression therapy with two surgical gloves sized one size too small worn on the dominant hand, which resulted in a decrease in fingertip temperature on the intervention side. Subjects received nab-paclitaxel every 3 weeks for four cycles. Outcomes were measured using the CTCAE and the PNQ and were recorded at baseline, before each treatment cycle, and 1 week after nab-paclitaxel was administered. CTCAE results demonstrated a decrease in the incidence of ≥ grade 2 peripheral neuropathy on the intervention side ( p< .0001). The occurrence of ≥ grade 2 sensory neurotoxicity decreased from 76.1% to 21.4%, and that of motor neurotoxicity decreased from 57.1% to 26.2%. Patient Neuropathy Questionnaire results demonstrated significantly lower grades of peripheral neuropathy on the intervention side ( p< .0001). Komen M. M., Smorenburg C. H., van den Hurk C. J., & Nortier J. W. (2013). Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist, 18( 7), 885–891. https://dx.doi.org/10.1634%2Ftheoncologist.2012-0332 [ PMC free article] [ PubMed] [ Google Scholar] Bandla A., Sundar R., Liao L. D., Sze Hui Tan S., Lee S. C., Thakor N. V., & Wilder-Smith E. P. (2016). Hypothermia for preventing chemotherapy-induced neuropathy - a pilot study on safety and tolerability in healthy controls. Acta Oncologica, 55( 4), 430–436. 10.3109/0284186X.2015.1075664 [ PubMed] [ CrossRef] [ Google Scholar] Similar benefit after subsequent chemo cycles (odds ratio: 0.59; 95% CI = 0.46–0.76, p< .0001), although analysis of impact of preexisting peripheral neuropathy not performed in statistics for late peripheral neuropathy group

The Impact of Peripheral Cooling on Chemotherapy-Induced

Seretny M., Currie G. L., Sena E. S., Ramnarine S., Grant R., MacLeod M. R.,...Fallon M. (2014). Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain, 155( 12), 2461–2470. 10.1016/j.pain.2014.09.020 [ PubMed] [ CrossRef] [ Google Scholar] Chemotherapy-induced peripheral neuropathy may be associated with decreased quality of life, reduced functional abilities, and may prevent patients from returning to work ( Miltenburg & Boogerd, 2014; Mols, Beijers, Vreugdenhil, & van de Poll-Franse, 2014; Tofthagen, 2010; Zanville et al., 2016). Functional limitations of CIPN relate to hand pain, hand numbness affecting fine motor skills, and foot pain and numbness, which may cause difficulty walking ( Bhatnagar et al., 2014; Zanville et al., 2016). Symptoms and severity of CIPN are also associated with an increased risk of falls ( Tofthagen, Overcash, & Kip, 2012). Symptoms of CIPN contribute to feelings of depression and loss of purpose when patients lose the ability to engage in activities they enjoy ( Tofthagen, 2010). The duration of CIPN symptoms ranges from months to years following treatment and may be permanent ( Miltenburg & Boogerd, 2014). No significant difference in Neuropathic Pain Symptom Inventory scores for symptoms in hands ( p> .15) or feet ( p> .30); no significant difference in quantitative sensory testing results ( p> .15); and pain severity using the Brief Pain Inventory was increased for all measures across time As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, Tofthagen C., Overcash J., & Kip K. (2012). Falls in persons with chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 20( 3), 583–589. 10.1007/s00520-011-1127-7 [ PMC free article] [ PubMed] [ CrossRef] [ Google Scholar]Small sample size with high dropout rate (29 down to 7) in part due to discomfort with intervention Griffiths C., Kwon N., Beaumont J. L., & Paice J. A. (2018). Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Supportive Care in Cancer, 26( 10), 3461–3469. 10.1007/s00520-018-4199-9 [ PubMed] [ CrossRef] [ Google Scholar] Symptoms assessed at baseline and before every cycle of paclitaxel administration during outpatient care Evaluation before the start of each cycle and 3 weeks after the last chemotherapy in the regional cooling group. Retrospective data from historical cohort provided data from comparable time points